Vitae Pharmaceuticals Announces Promotion of Tina Fiumenero to Chief Financial Officer

FORT WASHINGTON, Pa.--(Business Wire)--
Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company
dedicated to the discovery and development of innovative small
molecule medicines, announced today that it has promoted Tina
Fiumenero to the position of Chief Financial Officer.

"Tina's intense focus on building shareholder value and driving
capital efficiency have helped put Vitae in a strong financial
position," said Jeffrey Hatfield, Chief Executive Officer of Vitae.
"As Vitae continues to advance its growing pipeline, Tina's impressive
strategic and operational skills will help ensure Vitae's long-term
ability to succeed."

Ms. Fiumenero joined Vitae in January 2006 as Senior Vice
President, Finance and Administration. Prior to joining Vitae
Pharmaceuticals, Ms. Fiumenero spent 13 years at Bristol-Myers Squibb
where she held a held a number of finance positions of increasing
responsibility spanning U.S. commercial operations, mergers and
acquisitions and manufacturing. Prior to joining Bristol-Myers Squibb,
Ms. Fiumenero worked as a financial auditor for Coopers & Lybrand. She
holds a B.S. degree in accounting from New York University and is a
Certified Public Accountant.

Vitae Pharmaceuticals is an emerging pharmaceutical company with a
unique and powerful structure-based drug design engine and a rapidly
maturing portfolio of high value discovery programs. Vitae's goal is
to discover, develop and commercialize innovative new medicines, alone
and in partnership, that will be best-in-class in important
therapeutic areas such as cardiovascular and metabolic disease,
inflammation and CNS. Vitae Pharmaceuticals is financed by leading
corporate and venture capital investors and is headquartered in Fort
Washington, Pennsylvania. For additional information, please visit the
company's website, www.vitaepharma.com.

KMorrisPR
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com

Copyright Business Wire 2008